13F reference period
Q2 2026
Security Snapshot
Jazz Pharmaceuticals plc - COMMON STOCK (JAZZ) Institutional Ownership
CUSIP: G50871105
13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026
Institutions Reporting
648
Shares (Excl. Options)
64.37M
Full value: 64,369,280 · shares · 30 Jun 2026Price
$240.97
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- JAZZ on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 64,369,280
- Total 13F value
- $15,487,743,513
- Portfolio coverage rank
- 0.01%
- Share change
- -790,285
- Value change
- -$37,386,637
- Number of holders
- 648
- Shares outstanding
- 63,181,876
- SEC-reported price per share
- $231.52
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- JAZZ - Jazz Pharmaceuticals plc - COMMON STOCK is tracked under CUSIP G50871105.
- 648 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 575 to 648 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$12.28B
Full value: $12,283,859,694 · USD · 31 Mar 2026.$15.49B
Full value: $15,487,743,513 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 648 institutions filings for Q2 2026.
Security key
G50871105
13F reference period
Q2 2026
13F holders
648
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
JAZZ full holder history
Jazz Pharmaceuticals plc SEC filings
Jazz Pharmaceuticals plc company facts
Jazz Pharmaceuticals plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G50871105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
JAZZ
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 7.4% | $1,141,606,780 | 4,675,459 | FMR LLC | 30 Jun 2026 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $633,056,418 | 3,103,522 | Vanguard Capital Management | 31 Mar 2026 |
As of 30 Jun 2026,
648
institutional investors reported holding
shares of
Jazz Pharmaceuticals plc - COMMON STOCK (JAZZ).
This represents
102%
of the company’s total
outstanding shares.
64.37M
Full value: 64,369,280 · shares · 30 Jun 202663.18M
Full value: 63,181,876 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
69%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9.4% | 5,968,603 | +6.7% | 0.02% | $1,438,254,453 |
| FMR LLC | 7.3% | 4,609,326 | +103% | 0.05% | $1,110,709,035 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.8% | 3,036,213 | +1.8% | 0.03% | $731,636,247 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 2,729,650 | +3.1% | 0.01% | $657,763,761 |
| Capital World Investors | 4.3% | 2,697,610 | +0.91% | 0.08% | $650,043,082 |
| LSV ASSET MANAGEMENT | 3.6% | 2,275,145 | -4.7% | 0.99% | $548,242,000 |
| FRANKLIN RESOURCES INC | 3.2% | 2,040,250 | +4.2% | 0.11% | $491,639,148 |
| STATE STREET CORP | 3.2% | 1,999,816 | +5.7% | 0.01% | $481,895,662 |
| DIMENSIONAL FUND ADVISORS LP | 2.7% | 1,713,592 | -9.6% | 0.07% | $412,909,300 |
| FULLER & THALER ASSET MANAGEMENT, INC. | 2.6% | 1,638,544 | -2.2% | 1.1% | $394,839,917 |
| Bank of New York Mellon Corp | 2.5% | 1,578,013 | -6% | 0.06% | $380,253,849 |
| AQR CAPITAL MANAGEMENT LLC | 2.4% | 1,522,568 | +14% | 0.13% | $359,935,093 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 1,483,031 | +20% | 0.02% | $357,440,125 |
| AMERIPRISE FINANCIAL INC | 1.9% | 1,215,523 | -24% | 0.06% | $292,895,571 |
| JPMORGAN CHASE & CO | 1.8% | 1,160,786 | -3.6% | 0.02% | $276,634,191 |
| BANK OF AMERICA CORP /DE/ | 1.8% | 1,136,091 | +12% | 0.02% | $273,763,940 |
| CITADEL ADVISORS LLC | 1.6% | 1,006,676 | -20% | 0.14% | $242,578,716 |
| Swedbank AB | 1.5% | 968,092 | -2.4% | 0.2% | $233,281,128 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.3% | 799,297 | -9.7% | 0.19% | $192,606,598 |
| MILLENNIUM MANAGEMENT LLC | 1.2% | 763,880 | -39% | 0.12% | $184,072,164 |
| UBS Group AG | 1.2% | 756,865 | +112% | 0.03% | $182,381,760 |
| VICTORY CAPITAL MANAGEMENT INC | 1.1% | 686,719 | +168% | 0.09% | $165,478,678 |
| NORGES BANK | 1% | 656,843 | 0.02% | $158,279,458 | |
| MORGAN STANLEY | 1% | 629,680 | -9.9% | 0.01% | $151,734,512 |
| Mariner, LLC | 0.96% | 608,615 | +1421% | 0.15% | $146,630,968 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
51
Headline period
Q2 2026
Rows shown
1-25 of 51
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 1,952,026 | $450,824,854 | +$78,263,961 | $231.52 | 134 |
| 2026 Q2 | 64,369,280 | $15,487,743,513 | -$37,386,637 | $240.97 | 648 |
| 2026 Q1 | 65,045,899 | $12,283,859,694 | +$702,069,385 | $189.05 | 575 |
| 2025 Q4 | 61,702,488 | $10,480,482,425 | +$192,018,597 | $170.00 | 573 |
| 2025 Q3 | 60,646,127 | $7,990,617,646 | -$150,715,669 | $131.80 | 498 |
| 2025 Q2 | 61,824,515 | $6,561,677,298 | +$172,218,482 | $106.12 | 497 |
| 2025 Q1 | 59,973,813 | $7,442,798,617 | +$115,230,167 | $124.15 | 545 |
| 2024 Q4 | 59,002,163 | $7,265,494,814 | +$147,830,867 | $123.15 | 502 |
| 2024 Q3 | 57,597,455 | $6,415,433,594 | +$58,344,093 | $111.41 | 469 |
| 2024 Q2 | 57,463,700 | $6,133,341,626 | -$38,433,148 | $106.73 | 451 |
| 2024 Q1 | 57,711,183 | $6,947,614,300 | +$89,820,559 | $120.42 | 475 |
| 2023 Q4 | 57,060,984 | $7,017,863,210 | -$56,981,989 | $123.00 | 491 |
| 2023 Q3 | 56,530,271 | $7,318,098,320 | -$17,277,114 | $129.44 | 482 |
| 2023 Q2 | 56,728,151 | $7,039,068,770 | -$22,114,573 | $123.97 | 465 |
| 2023 Q1 | 56,681,319 | $8,292,329,555 | +$108,158,178 | $146.33 | 462 |
| 2022 Q4 | 56,178,304 | $8,948,272,058 | -$100,056,709 | $159.31 | 475 |
| 2022 Q3 | 56,928,016 | $7,590,657,250 | -$96,379,512 | $133.29 | 443 |
| 2022 Q2 | 57,260,089 | $8,932,716,610 | +$138,065,500 | $156.01 | 448 |
| 2022 Q1 | 56,748,008 | $8,837,789,303 | -$111,358,494 | $155.67 | 437 |
| 2021 Q4 | 57,664,502 | $7,350,056,970 | +$21,422,030 | $127.40 | 422 |
| 2021 Q3 | 56,879,540 | $7,407,482,783 | -$119,725,201 | $130.21 | 422 |
| 2021 Q2 | 57,178,368 | $10,156,395,395 | +$780,868,772 | $177.64 | 481 |
| 2021 Q1 | 53,127,709 | $8,729,942,643 | +$29,540,811 | $164.37 | 435 |
| 2020 Q4 | 52,654,654 | $8,685,222,791 | -$294,935,573 | $165.05 | 428 |
| 2020 Q3 | 54,543,371 | $7,767,396,418 | +$369,110,226 | $142.59 | 382 |